Sight Sciences, Inc. (SGHT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 22, 2026, discloses a material legal development for Sight Sciences, Inc. The filing addresses the conclusion of patent infringement litigation initiated in September 2021 against Alcon Inc. and related entities regarding the Hydrus Microstent.
Key Financial Metrics and Legal Award
The U.S. District Court for the District of Delaware entered a Final Judgment awarding the Company total monetary damages of $55.4 million. The award breakdown is as follows:
- Past Damages: $34.0 million (covering sales from first commercial sale through April 26, 2024).
- Supplemental Damages: $14.7 million (covering the period from April 26, 2024, through March 31, 2026).
- Interest: $6.8 million (pre-judgment and post-judgment interest through April 17, 2026).
- Ongoing Royalty: 10% of Hydrus revenue until the expiration of the last asserted patent.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the Company's general operations, as this report focuses solely on the litigation outcome.
Material Changes and Conditions
The Final Judgment upheld the validity of three Sight Sciences patents (U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328) and found that Alcon willfully infringed them. However, the receipt of monetary damages is conditional. No funds will be received unless and until Alcon exhausts its appeal rights and the judgment is affirmed, or the time for filing an appeal expires. Interest and royalties will continue to accrue during any appeal period.
Outlook, Risks, and Contingencies
Appeal Risk: The Final Judgment is subject to appeal by Alcon to the United States Court of Appeals for the Federal Circuit. Collection of damages is contingent upon a favorable final and non-appealable judgment.
Patent Validity Risk: Alcon has initiated ex parte reexamination proceedings seeking to invalidate the asserted patent claims. If an adverse, final, and non-appealable judgment is entered in these proceedings before a favorable final judgment in the litigation, it could negatively affect the Company's ability to collect on the Final Judgment.
Investor Verification Checklist
- Confirm the status of Alcon's appeal to the Federal Circuit and any associated timelines.
- Monitor the progress of ex parte reexamination proceedings initiated by Alcon to challenge patent validity.
- Verify the Company's cash position and liquidity needs given the delay in receiving the $55.4 million award.
- Assess the potential impact of the 10% ongoing royalty on future revenue streams once the judgment becomes final.